NeoTract has unveiled positive data from two studies evaluating its UroLift system, a minimally invasive implant designed to treat urinary tract symptoms due to benign prostatic hyperplasia.
Data from a pivotal, LIFT IDE study show the system demonstrated sustained symptom relief, quality of life and urinary flow at four years, the company says. Further, 86 percent of patients did not have to seek additional treatment.
In a two-year BPH-6 study, the system demonstrated superiority compared to the surgical standard, transurethral resection of the prostate.
The company presented the data at the annual American Urological Association meeting in San Diego. — Anisa Jibrell